Experimental Nasal Influenza Vaccine Tested in Kids, Teens
September 17, 2018
September 17, 2018
WASHINGTON, Sept. 17 -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
An early-stage clinical trial testing the safety and immune-stimulating ability of an experimental nasal influenza vaccine in healthy 9- to 17-year-old children and teens has begun enrolling participants at a Vaccine and Treatment Evaluation Unit (VTEU) site at Saint Louis University, Missouri. The VTEU is funded by the National Institute of Alle . . .
An early-stage clinical trial testing the safety and immune-stimulating ability of an experimental nasal influenza vaccine in healthy 9- to 17-year-old children and teens has begun enrolling participants at a Vaccine and Treatment Evaluation Unit (VTEU) site at Saint Louis University, Missouri. The VTEU is funded by the National Institute of Alle . . .